All storiesMetabolic health

AAO: Association between GLP-1 receptor agonists and age-related macular degeneration explored

A new study presented at the American Academy of Ophthalmology meeting examines whether drugs called GLP-1 receptor agonists change the risk of developing age-related macular degeneration (AMD). Initial analysis suggested higher risk, but adjusting for heart and metabolic conditions reversed this finding.

NeoMD Editors · 2026-10-22 · 02:48 AM EDT

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

Initial crude analysis suggested a possible increased risk of AMD among GLP-1 receptor agonist users, but this risk reversed after adjusting for cardiometabolic factors.
Adjusted analysis indicates that underlying cardiometabolic health conditions influence AMD risk more than GLP-1 RA use itself.
The study’s limited available data means results are preliminary and further research is needed to understand long-term eye health effects.

Editorial illustration for AAO: Association between GLP-1 receptor agonists and age-related macular degeneration explored — AI-generated editorial illustration.

Researchers investigated whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a class of medications commonly used for diabetes and weight management—affect the risk of developing age-related macular degeneration (AMD), a leading cause of vision loss in older adults.

What Did the Study Find?

In a first look at the data, crude odds ratios indicated that people using GLP-1 RAs might have an increased risk of AMD. Crude odds ratios mean the raw comparison between users and non-users without considering other factors.

However, when researchers adjusted their analysis to account for cardiometabolic factors—like heart disease, diabetes, and other metabolic health conditions that can influence AMD risk—the association reversed. This suggests that the apparent increased risk was influenced by these confounding health conditions rather than GLP-1 RA use itself.

Understanding the Evidence and Its Limits

Supporting editorial illustration for AAO: Association between GLP-1 receptor agonists and age-related macular degeneration explored — AI-generated editorial illustration.

This analysis was presented at the American Academy of Ophthalmology's 2026 annual meeting but details such as study size, design, and population were not provided in the available summary.

Since the study adjusted for cardiometabolic variables, it highlights the importance of considering underlying health conditions that affect both AMD and the need for GLP-1 RA treatment.

Because these factors are strongly linked to AMD risk, initial crude associations may be misleading. Adjusted results provide a clearer picture but do not prove that GLP-1 RAs completely eliminate risk or are protective.

What Does This Mean for Patients?

The current evidence does not show that GLP-1 receptor agonists increase the risk of AMD once other health factors are taken into account. However, more detailed research is needed to confirm these observations and understand any potential long-term effects on eye health.

Patients using or considering GLP-1 RAs should consult their healthcare providers about the benefits and risks of these medications based on their overall health profile.

Source: Medical Xpress